Receptor for advanced glycation end-product (RAGE) gene polymorphism 2245G/A is associated with pro-inflammatory, oxidative-glycation markers and sRAGE in diabetic retinopathy

Gene

Volumn 521, Issue 2, 2013, Pages 227-233

  Ng, Zhi Xiang ^a   Kuppusamy, Umah Rani ^a   Iqbal, Tajunisah ^a   Chua, Kek Heng ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Advanced oxidation protein product; Antioxidant; Monocyte chemoattractant protein 1; Nuclear factor kappa B; Pentosidine

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED OXIDATION PROTEIN PRODUCT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; GLUTATHIONE PEROXIDASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOSIDINE; SUPEROXIDE DISMUTASE; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; WILD TYPE;

ADULT; ADVANCED OXIDATION PROTEIN PRODUCTS; AGED; ARGININE; BIOLOGICAL MARKERS; CHEMOKINE CCL2; DIABETIC RETINOPATHY; FEMALE; GENOTYPE; GLUTATHIONE PEROXIDASE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; LYSINE; MALE; MIDDLE AGED; NF-KAPPA B; POLYMORPHISM, GENETIC; RECEPTORS, IMMUNOLOGIC; SUPEROXIDE DISMUTASE;

EID: 84876996605     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.03.062     Document Type: Article

References (29)

1. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
2. Boyum A. Separation of leukocytes from blood and bone marrow. Introduction. Scand. J. Clin. Lab. Invest. 1968, Suppl. 97:7.
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
4. Cai J., Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye (Lond.) 2002, 16:242-260.
5. Christiansen T., Richelsen B., Bruun J.M. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int. J. Obes. (Lond) 2005, 29:146-150.
6. Diabetic retinopathy study Report Number 6. Design, methods, and baseline results. Report number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 1981, 21:1-226.
7. Early Treatment Diabetic Retinopathy Study Research Group Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991, 98:823-833.
8. Early Treatment Diabetic Retinopathy Study Research Group Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991, 98:786-806.
9. Goh P.P. Status of diabetic retinopathy among diabetics registered to the Diabetic Eye Registry, National Eye Database, 2007. Med. J. Malaysia 2008, 63 Suppl C:24-28.
10. Ho E., Bray T.M. Antioxidants, NFkappaB activation and diabetogenesis. Proc. Soc. Exp. Biol. Med. 1999, 222:205-213.
11. Hudson B.I., Stickland M.H., Futers T.S., Grant P.J. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001, 50:1505-1511.
12. Hudson B.I., et al. Glycation and diabetes: the RAGE connection. Curr. Sci. 2002, 83:1515-1521.
13. Kalea A.Z., Reiniger N., Yang H., Arriero M., Schmidt A.M., Hudson B.I. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J. 2009, 23:1766-1774.
14. Kalousova M., Zima T., Tesar V., Dusilova-Sulkova S., Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat. Res. 2005, 579:37-46.
15. Kalousova M., et al. Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol. Dial. Transplant. 2007, 22:2020-2026.
16. Kankova K., et al. Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism 2001, 50:1152-1160.
17. Kumaramanickavel G., Ramprasad V.L., Sripriya S., Upadyay N.K., Paul P.G., Sharma T. Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients. J. Diab. Complications 2002, 16:391-394.
18. Moore T.C., et al. The role of advanced glycation end products in retinal microvascular leukostasis. Invest. Ophthalmol. Vis. Sci. 2003, 44:4457-4464.
19. Ng Z.X., Kuppusamy U.R., Tajunisah I., Fong K.C., Chua K.H. Association analysis of -429T/C and -374T/A polymorphisms of receptor of advanced glycation end products (RAGE) gene in Malaysian with type 2 diabetic retinopathy. Diabetes Res. Clin. Pract. 2012, 95:372-377.
20. Ng Z.X., Kuppusamy U.R., Tajunisah I., Fong K.C., Koay A.C., Chua K.H. 2245G/A polymorphism of the receptor for advanced glycation end-products (RAGE) gene is associated with diabetic retinopathy in the Malaysian population. Br. J. Ophthalmol. 2012, 96:289-292.
21. Ng Z.X., et al. Lack of association between Gly82Ser, 1704G/T and 2184A/G of RAGE gene polymorphisms and retinopathy susceptibility in Malaysian diabetic patients. Genet. Mol. Res. 2012, 11:455-461.
22. Ng Z.X., Chua K.H., Tajunisah I., Pendek R., Kuppusamy U.R. Attenuated levels of pro-inflammatory markers in diabetic retinopathy patients undergoing treatment with antihyperglycemic and antihypertensive drugs. Clinics 2013, 68:185-193.
23. Ozturk B.T., Bozkurt B., Kerimoglu H., Okka M., Kamis U., Gunduz K. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol. Vis. 2009, 15:1906-1914.
24. Pachydaki S.I., et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp. Eye Res. 2006, 82:807-815.
25. Schlueter C., Hauke S., Flohr A.M., Rogalla P., Bullerdiek J. Tissue-specific expression patterns of the RAGE receptor and its soluble forms-a result of regulated alternative splicing?. Biochim. Biophys. Acta 2003, 1630:1-6.
26. Schmidt A.M., Stern D.M. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol. Metab. 2000, 11:368-375.
27. Uthra S., et al. Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort. Ophthalmic Genet. 2008, 29:11-15.
28. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
29. Witko-Sarsat V., et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996, 49:1304-1313.